about
Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysisImmunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysisThe state of multiple sclerosis: current insight into the patient/health care provider relationship, treatment challenges, and satisfactionSafety of monoclonal antibodies for the treatment of multiple sclerosis.Pharmacokinetic evaluation of fingolimod for the treatment of multiple sclerosis.Metabolic and safety issues for multiple sclerosis pharmacotherapy--opportunities for personalised medicine.Inflammatory manifestations of HTLV-1 and their therapeutic options.Peginterferon beta-1a: a review of its use in patients with relapsing-remitting multiple sclerosis.Immunomodulatory therapies for relapsing-remitting multiple sclerosis: monoclonal antibodies, currently approved and in testing.PEGylated IFNβ-1a in the treatment of multiple sclerosis.A Recombinant Bispecific CD20×CD95 Antibody With Superior Activity Against Normal and Malignant B-cells.Perspectives of ofatumumab as CD20 targeted therapy in rheumatoid arthritis and other autoimmune diseases.Population Pharmacokinetics of Daclizumab High-Yield Process in Healthy Volunteers and Subjects with Multiple Sclerosis: Analysis of Phase I-III Clinical Trials.Population PK-PD analyses of CD25 occupancy, CD56bright NK cell expansion, and regulatory T cell reduction by daclizumab HYP in subjects with multiple sclerosis.The therapeutic potential of Rho kinase inhibitor fasudil derivative FaD-1 in experimental autoimmune encephalomyelitis.Beneficial effects of fingolimod in MS patients with high serum Sema4A levels.
P2860
Q24187126-7BBA2696-1B96-41BF-9C22-ED7B4BF772DFQ24188270-45066A25-E432-495C-8742-FA18894E189BQ30275099-941EFF46-6C71-4D52-9B8F-876B72144A75Q34542922-A45D57A2-FFF9-4A98-8251-2E335E2760B5Q38192006-6AECD627-65CD-45A5-9C53-CC5FA33E7751Q38218692-0D12A4BD-0285-467C-8847-597A91C171DDQ38262169-4305CD59-35AB-4A9F-9E68-9E21F96D34DDQ38349772-16ECD43D-B6E2-4E37-983B-933D6EC34632Q38444543-A1DA4CD8-DC6B-4C9B-8AD0-F6B801A7228AQ38513495-CA8A58F9-AAE2-4265-A30D-80CC2B5363CFQ38818670-ED69263A-7D00-4F0E-8ABB-2DFCF2B271FFQ38916526-B67711D2-53E7-498A-A34C-195DEBD2CE85Q40000217-08F4B7B5-0D9E-4C4D-96D9-3F059EEF31C8Q42700892-EAD68C64-3F62-4442-B8F2-2080A88D47C7Q48541667-98EBADB2-315B-4587-876E-80B688EF5AD0Q53703709-04C036BF-990F-4319-8C89-86BEE401B55D
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Emerging injectable therapies for multiple sclerosis.
@en
type
label
Emerging injectable therapies for multiple sclerosis.
@en
prefLabel
Emerging injectable therapies for multiple sclerosis.
@en
P1433
P1476
Emerging injectable therapies for multiple sclerosis.
@en
P2093
P304
P356
10.1016/S1474-4422(13)70192-3
P577
2013-10-01T00:00:00Z